Oligovax is an biopharmaceutical company focused on developing innovative therapies for cancer.

The company's lead molecule, Litenimod, is a potent agonist of Toll-Like Receptor 9 (TLR9), triggering both innate and adaptive immune responses. Such a mode of action offers the potential to use Litenimod either alone, or as a vaccine adjuvant, or combined to monoclonal Antibodies.

Oligovax has clinical trials underway in cancer, and is conducting pre-clinical studies using Litenimod as an adjuvant in vaccines and/or immunotherapeutic approaches.


November 2012
Publication of the patent filed in may 2012 by the AP/HP: “combination of Litenimod and anti-angiogenic agents”.

July 2012
Pr Antoine Carpentier received the 2012 "Meilleur brevet " Award from the Assistance Publique-Hopitaux de Paris (AP/HP) for a patent combining TLR9 agonists and anti-angiogenic agents. Christian Lamoureux, board director of the LEEM, and Mireille Faugère, board director of AP-HP, with the French Patent Office and the CDC bank gave the award to Pr Antoine Carpentier during the APinnov 2012 meeting.

March 2012
Inclusions in the phase 1 trial in tumoral meningitis have been completed. Results of the trial should be disclosed at the ASCO-2013 meeting in Chicago, US.
  1. Carpentier AF, Chen L, Maltonti F, Delattre JY. (1999). Oligodesoxynucleotides containing CpG motifs can cure neuroblastoma in mice. Cancer Research, 59, 5429-5432.

  2. Carpentier AF, Xie J, Mokthari K, Delattre JY. (2000). Successful treatment of intracranial gliomas in rats with oligodeosynucleotides containing CpG motifs. Clinical Cancer Research, 6: 2469-73.

  3. Auf G, Carpentier AF, Chen L, Le Clanche C, Delattre JY. (2001). Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin Cancer Res; 7: 3540-3.
More publications...